Reports Q4 revenue $2.29B, consensus $2.25B. “We delivered strong revenue growth in our base business of 7% for the full year 2023 and delivered on our earnings commitment as we transitioned away from COVID testing,” said Jim Davis, chairman, CEO, and president. “We made progress during the year advancing our growth strategy with innovative testing solutions, new and expanded relationships with health systems, and a robust pipeline of M&A and professional lab services opportunities. We also delivered double-digit revenue growth in several clinical areas, including in advanced cardiometabolic, prenatal and hereditary genetics, and neurology, as well as strengthened our oncology offering with a strategic investment in higher growth minimal residual disease testing.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quest Diagnostics price target lowered to $152 from $153 at JPMorgan
- Quest Diagnostics and Fitbit announce collaboration to study wearable devices
- Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System